BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29689646)

  • 1. Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
    Wilding JPH
    Clin Obes; 2018 Jun; 8(3):211-225. PubMed ID: 29689646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
    Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
    Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.
    Pantalone KM; Smolarz BG; Ramasamy A; Baz Hecht M; Harty BJ; Rogen B; Griebeler ML; Borukh E; Young JB; Burguera B
    JAMA Netw Open; 2021 Jul; 4(7):e2116595. PubMed ID: 34255049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
    Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B
    Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistence of newer anti-obesity medications in a real-world setting.
    Ganguly R; Tian Y; Kong SX; Hersloev M; Hobbs T; Smolarz BG; Ramasamy A; Haase CL; Weng W
    Diabetes Res Clin Pract; 2018 Sep; 143():348-356. PubMed ID: 30009937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA
    R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K; Braverman-Panza J
    J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacotherapy for obesity].
    van Rossum EFC; Welling MS; van der Voorn B; van der Valk ES; Abawi O; van den Akker ELT
    Ned Tijdschr Geneeskd; 2021 Jan; 165():. PubMed ID: 33560612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for obesity: What you need to know.
    Bersoux S; Byun TH; Chaliki SS; Poole KG
    Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US.
    Czepiel KS; Perez NP; Campoverde Reyes KJ; Sabharwal S; Stanford FC
    Front Endocrinol (Lausanne); 2020; 11():290. PubMed ID: 32477270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
    Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
    BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
    Ahmad NN; Robinson S; Kennedy-Martin T; Poon JL; Kan H
    Obes Rev; 2021 Nov; 22(11):e13326. PubMed ID: 34423889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for Obesity.
    Saunders KH; Shukla AP; Igel LI; Kumar RB; Aronne LJ
    Endocrinol Metab Clin North Am; 2016 Sep; 45(3):521-38. PubMed ID: 27519128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Use of Pharmacotherapy for Obesity.
    Igel LI; Kumar RB; Saunders KH; Aronne LJ
    Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.